Stockreport

Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) [Yahoo! Finance]

Lexicon Pharmaceuticals, Inc.  (LXRX) 
Last lexicon pharmaceuticals, inc. earnings: 4/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: lexpharma.com/investors
PDF neuropathic pain (DPNP). The study enrolled 494 patients, exceeding the original target, and top-line data is expected in Q1 2025. LX9211 is a novel, orally-delivered in [Read more]